Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/TCTR20190806005
TCTR20190806005Not yet recruitingPhase 4

Bioequivalence study of tadalafil 5 mg film-coated tablet in Thai healthy volunteers

Faculty of Medicine, Chulalongkorn University0 sites60 target enrollmentStarted: August 6, 2019Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Sponsor
Enrollment
60
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to 50 Years (—)
Sex
Male

Inclusion Criteria

  • •1. Subjects who are Thai male, aged 18 to 50 years (inclusive).
  • •2. Subjects whose BMI is 18.0-25.0 kg/m2 (inclusive).
  • •3. Subjects who are healthy by medical history, physical examination, vital signs and EKG.
  • •4. Subject whose screening visit laboratory values of blood tests including complete blood count, fasting blood sugar, blood urea nitrogen, serum creatinine, alkaline phosphatase, ALT, AST, total bilirubin, albumin are within the normal range or showing no clinically significant abnormalities as confirmed by the clinical investigator. HBsAg is negative.
  • •5. Subjects are able to understand the requirements of the study and voluntarily sign and date an informed consent, approved by the Independent Ethic Committee (IEC)/ Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures
  • •6. Alcohol breath test is negative.

Exclusion Criteria

  • •1. Subjects who are with a history/evidence of drug sensitivity or allergic reaction to tadalafil, or any related drug.
  • •2. Subjects who have a history of any illness that, in the opinion of the clinical investigator, might confound the result of the study or pose an additional risk in administrating study drug to the subjects.
  • •3. Subjects who have significant of abnormal EKG (depend on clinical investigator decision).
  • •4. Subjects who are with a history of heavy smoking (more than 10 cigarettes per day) or moderate smoking (less than 10 cigarettes per day) and cannot omit smoking at least three days before the study and until the completion of the study period.
  • •5. Subjects who are with a history of alcoholic (more than 2 years) or for men, more than 4 drinks on any single day and more than 14 drinks per week.
  • •6. Subjects who are with a history of any drug abuse. eg. Morphine, methamphetamine, tetrahydrocannabinol (marijuana).
  • •7. Subjects who receive of any medical prescription, herbal medicine and food supplement within 14 days before the first administration of the study drug, especially drug related to the study drug metabolizing enzyme.
  • •8. Subjects who are participating in any investigational drug study or had been in any investigational drug study within 3 months prior to the screening visit.

Investigators

Sponsor
Faculty of Medicine, Chulalongkorn University

Similar Trials

Recruiting
Not Applicable
Investigating the in vivo bioequivalence of Tadalafil 5 mg tabletIn the present study, the products will be administered to healthy volunteers..
IRCT20210519051345N22Tabriz University of Medical Sciences24
Recruiting
Not Applicable
In-vivo Bioequivalence study of Tadalafil tablet with brand drugs (CIALIS Lilly USA)
IRCT20200105046010N39Mofid Pharmaceutical Co.24
Completed
Not Applicable
The effect of tadalafil compared to tamsulosin and placebo on the symptoms of double-J stent insertion in men with ureter stonesCondition 1: Lower urinary tract symptoms. Condition 2: Pain in the flank and suprapubic areas. Condition 3: Sexual function.Calculus of lower urinary tractOther and unspecified abdominal painUnspecified sexual dysfunction, not caused by organic disorder or disease
IRCT201702261853N13rology Research Centre, Guilan University of Medical Sciences120
Active, not recruiting
Phase 4
The effect of tadalafil in the treatment of erectile dysfunction in patients with chronic renal failureerectile dysfunctionend stage renal diseasehaemodialysiskidney transplantRenal DialysisKidney TransplantationErectile DysfunctionKidney Failure, Chronic
TCTR20220310008rology-Nephrology Research Center of Shahid Beheshti University of Medical Sciences45
Not yet recruiting
Phase 4
A study to compare the beneficial effect and safety of tadalafil compared to sildenafil in pulmonary hypertensive patients due to lung disease
CTRI/2024/06/069470Midhun Sakravarthy J